MARKET

PPH

PPH

Vaneck Vectors Pharmaceutical Etf
NASDAQ

Real-time Quotes | Provided by Morningstar

78.11
+2.03
+2.67%
Closed 16:00 06/24 EDT
OPEN
77.08
PREV CLOSE
76.08
HIGH
78.14
LOW
76.88
VOLUME
113.76K
TURNOVER
5.35M
52 WEEK HIGH
84.27
52 WEEK LOW
70.40
TOTAL ASSET
512.95M
YTD YIELD
7.01%
1D
5D
1M
3M
1Y
5Y
Biotech outperforms as deal making heats up
Biotech stocks have made record gains on Friday amid signs of heightened deal making activity in the beaten down industry. SPDR S&P Biotech ETF (XBI) and iShares Nasdaq Biotechnology ETF
Seekingalpha · 06/17 18:07
Wealth Shock Delays Gold Bull Market as Goldman Revises Targets
Bloomberg · 06/15 02:00
Father of VIX Wades Into Bitcoin ETF Battle to Back Grayscale Bid
Bloomberg · 06/01 14:14
FEMA Fund Debuts as Natural Disasters Grow More Damaging, Costly
Bloomberg · 06/01 13:00
First Crypto ETFs in Australia See Trading Evaporate
Bloomberg · 06/01 10:38
DWS Replaces CEO After Police Raid in Greenwashing Probe
Bloomberg · 06/01 03:47
BioPharma M&A premiums could moderate amid rate hikes – Wells Fargo
Citing data from 1995, Wells Fargo argues that for every half a percentage point increase in treasury yield, there is a 5.6% decrease in the average deal premium paid in
Seekingalpha · 05/28 16:22
SEC Planned Crackdown on ‘Misleading’ Funds Goes Far Beyond ESG
Bloomberg · 05/26 19:34
More
No Data
Learn about the latest financial forecast of PPH. Analyze the recent business situations of Vaneck Vectors Pharmaceutical Etf through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
Ratings
Date
Period
Agency
Ratings
05/31/2022
3 Year
Morningstar
05/31/2022
5 Year
Morningstar
05/31/2022
10 Year
Morningstar
  • Performance
  • Asset Allocation
  • Dividend History
Period
Return
Rank in Cat
1-Day
8.5700%
--
1-Month
-3.2996%
--
3-Month
3.8952%
--
6-Month
6.1141%
--
1-Year
8.7407%
--
3-Year
44.3795%
--
5-Year
50.6902%
--
10-Year
162.7155%
--
No Data
No Data
No Data
Profile
Fund Name
Vaneck Vectors Pharmaceutical Etf
Inception Date
2011-12-20
Benchmark
MVIS US Listed Pharmaceutical 25 NR USD
Advisor Company
Van Eck Associates Corporation
Custodian
State Street Bank and Trust Company
Manager
Peter Liao, Guo Hua (Jason) Jin